On November 18, 2022 Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported data from three posters that are being presented at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting (Press release, Kintara Therapeutics, NOV 18, 2022, View Source [SID1234624247]). The 2022 SNO Annual Meeting is being held from November 16 through November 20, 2022 in Tampa, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three posters on VAL-083 are being presented as follows:

Phase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed, MGMT-unmethylated GBM
Poster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

The first poster presented two case reports from the open-label, Phase 2 study of VAL-083 as a first-line treatment in newly-diagnosed, unmethylated GBM patients conducted at Sun Yat-sen University Cancer Center in China. These two patients, a 32-year-old woman and a 49-year-old man, have remained alive 53 months and 35 months, respectively, as of the October 2022 poster cut-off date.

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

The second poster reported on a patient with recurrent RELA fusion-positive ependymoma who was treated with VAL-083 for 12 cycles under expanded access. Eighteen months after completion of treatment with VAL-083, the patient remains neurologically and radiologically stable with no evidence of disease.

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

The third poster presented information on fourteen patients with recurrent GBM who were treated at MD Anderson Cancer Center under expanded access. Eight of these patients received four or more cycles of VAL-083, with one patient receiving 18 cycles. Data was also presented for five patients who received VAL-083 in combination with bevacizumab without any hematological adverse events.